Sarcoidosis and uveitis are chronic inflammatory conditions with potentially debilitating effects on quality of life. Steroids form the mainstay standard therapy in both conditions. Biologic agents are considered to be appropriate alternatives for treatment in steroid-refractory sarcoidosis and uveitis due to the role of tumor necrosis factor (TNF) in mediating the inflammatory cascade seen in both conditions. We performed a thorough literature search using PubMed to compare the extent of use, efficacy, and safety profile of individual anti-TNF agents in the management of these conditions. Our review consists of two systematic reviews with meta-analysis, thirteen observational studies, and fifteen case series/reports. Infliximab had the widest range of organ-system usage in extra-pulmonary sarcoidosis but is equivalent to adalimumab in terms of efficacy. In uveitis, adalimumab was found to be the most efficacious agent for maintaining disease remission in adults and children with chronic non-infectious uveitis. Etanercept was neither used widely, nor was it efficacious in the management of either condition. In terms of safety profile, biologic agents were found to be well tolerated and have a similar safety profile. More randomized clinical trials are needed to inform evidence-based use of biologic agents in these conditions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413313 | PMC |
http://dx.doi.org/10.7759/cureus.9057 | DOI Listing |
J Biol Methods
November 2024
Department of Medicine and Surgery, University of Enna Kore, Enna 94100, Italy.
Background: Anterior uveitis is a common manifestation in individuals with rheumatic conditions such as spondylarthritis, Behçet's syndrome, juvenile idiopathic arthritis, and sarcoidosis. Clinical differentiation between granulomatous and non-granulomatous corneal endothelial exudates is crucial to subsequent diagnosis and treatment. Anterior segment optical coherence tomography (AS-OCT) can ensure an accurate differential diagnosis and appropriate follow-up after local and systemic therapy.
View Article and Find Full Text PDFOcul Immunol Inflamm
January 2025
Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.
Purpose: This study aimed to investigate demographic features, diagnoses of uveitis (intraocular inflammation), and real-world clinical practice in the use of local and systemic therapies for patients with uveitis in Tokyo, Japan.
Methods: Clinical records of 1,174 consecutive new patients (480 males, 694 females) referred to the Kyorin Eye Center, Kyorin University Hospital between January 2011 and December 2018 were retrospectively reviewed.
Results: Mean age at presentation was 52.
Ophthalmol Retina
December 2024
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas.
BMJ Case Rep
December 2024
Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UK.
Sarcoidosis is a systemic granulomatous disease with variable ocular involvement. The most common ocular manifestation is uveitis, which can have potentially sight threatening complications such as glaucoma. We present the case of a man in his 30s with sarcoidosis and recurrent anterior uveitis, necessitating surgical intervention to control intraocular pressure and prevent further glaucomatous optic neuropathy progression.
View Article and Find Full Text PDFOcul Immunol Inflamm
December 2024
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!